PubRank

Richard M Weinshilboum

Author PubWeight™ 114.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005 5.92
2 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009 5.05
3 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2006 4.35
4 Genomics and drug response. N Engl J Med 2011 4.35
5 Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008 3.48
6 Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010 3.02
7 Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006 1.96
8 Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res 2007 1.75
9 Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009 1.75
10 Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 2006 1.74
11 Human aromatase: gene resequencing and functional genomics. Cancer Res 2005 1.71
12 A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics 2004 1.65
13 Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet 2008 1.41
14 Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010 1.37
15 Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet 2006 1.37
16 Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 2012 1.34
17 Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006 1.33
18 CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2012 1.33
19 Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 2010 1.30
20 Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006 1.30
21 A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2006 1.25
22 Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005 1.23
23 Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010 1.21
24 Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A 2005 1.20
25 Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos 2006 1.17
26 Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010 1.14
27 Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clin Proc 2004 1.14
28 Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res 2012 1.13
29 Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 2013 1.12
30 Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci 2010 1.11
31 Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 2006 1.10
32 Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res 2008 1.09
33 CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011 1.09
34 Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record. J Am Med Inform Assoc 2011 1.09
35 Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 2002 1.09
36 Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genet Epidemiol 2011 1.06
37 Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014 1.05
38 Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization. Mol Genet Metab 2008 1.05
39 Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 2010 1.04
40 TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol 2013 1.02
41 Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol 2003 1.00
42 Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 2011 0.98
43 Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem 2005 0.98
44 A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev 2007 0.96
45 Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008 0.95
46 Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol 2014 0.94
47 Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol 2009 0.94
48 The genomic revolution and medicine. Mayo Clin Proc 2002 0.94
49 Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol 2008 0.93
50 Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 2004 0.92
51 Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J Neurochem 2003 0.91
52 SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 2011 0.90
53 Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003 0.90
54 Thiopurine pathway. Pharmacogenet Genomics 2010 0.90
55 FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 2013 0.90
56 N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002 0.90
57 Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Mol Genet Metab 2010 0.89
58 Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med 2012 0.89
59 Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol Exp Ther 2007 0.89
60 Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem 2012 0.88
61 Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet Genomics 2009 0.87
62 Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet Genomics 2009 0.87
63 Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol 2010 0.87
64 Methionine adenosyltransferase 2A/2B and methylation: gene sequence variation and functional genomics. Drug Metab Dispos 2011 0.87
65 Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics 2008 0.87
66 The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med 2014 0.86
67 Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ Cardiovasc Genet 2013 0.86
68 Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics 2011 0.86
69 Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008 0.84
70 Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes. Pharmacogenetics 2002 0.84
71 Structural basis of substrate recognition in thiopurine s-methyltransferase. Biochemistry 2008 0.84
72 Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 2014 0.83
73 Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen. Int Immunopharmacol 2011 0.83
74 Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol 2014 0.83
75 Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach. BMC Genomics 2010 0.83
76 Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization. J Neurochem 2009 0.82
77 Mammographic breast density response to aromatase inhibition. Clin Cancer Res 2013 0.82
78 Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochem Biophys Res Commun 2004 0.82
79 Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos 2010 0.81
80 Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006 0.81
81 Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos 2012 0.81
82 Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol 2009 0.80
83 CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leuk Lymphoma 2010 0.80
84 TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenet Genomics 2013 0.79
85 Pharmacogenetics of human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1): gene resequencing, sequence variation, and functional genomics. Biochem Pharmacol 2003 0.79
86 Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos 2002 0.78
87 Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics 2008 0.78
88 Cat red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. J Pharmacol Exp Ther 2003 0.78
89 Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics 2013 0.78
90 PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet Genomics 2012 0.78
91 Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metab Dispos 2007 0.78
92 Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies. Genet Epidemiol 2013 0.77
93 Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. Pharmacogenetics 2002 0.76
94 Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy in recently postmenopausal white women. Menopause 2016 0.75
95 Interview: Richard M Weinshilboum talks to Hannah Branch, Assistant Commissioning Editor. Biomark Med 2013 0.75
96 Thiopurine methyltransferase activity in red blood cells of dogs. J Vet Intern Med 2004 0.75
97 Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure. Pac Symp Biocomput 2018 0.75
98 An interview with Pharmacogenomics for the breast cancer special focus issue. Pharmacogenomics 2012 0.75
99 Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer 2007 0.75